Global Drugmakers Use AI to Transform Marketing and Sales

Global pharmaceutical companies have traditionally focused their artificial-intelligence efforts on drug discovery. The industry has recently found, however, that sales and marketing are where AI can deliver the most tangible financial benefits. With the global biopharmaceutical marketing sector eyeing a vast new opportunity worth NT$25 trillion, using AI to optimize promotional strategies has become crucial for industry leaders such as Pfizer and Johnson & Johnson to sharpen their competitive edge.

As of July 2026, multinational drugmakers including Pfizer, Merck and Johnson & Johnson had introduced proprietary AI platforms. The latest developments show that these technologies have cut marketing-content production from several weeks to just minutes, improving efficiency nearly 100-fold. The shift has not only streamlined sales processes but also enabled drugmakers to adjust their engagement strategies with physicians in real time as healthcare markets change rapidly.